SUMMARY
This is AI generated summarization, which may have errors. For context, always refer to the full article.
Swiss pharmaceuticals giant Novartis is researching a vaccine for the H7N9 strain of bird flu, its chief executive said Thursday, April 25, amid fears that the disease could mutate into a form that spreads among people. In an interview with the Swiss daily Tagesanzeiger, Joe Jimenez said that Novartis had already analysed the virus’ genetic codes, which have been published by Chinese authorities. Jimenez said that Novartis “would today be in a position to develop a vaccine for initial clinical trials within six to eight weeks”.
Read the full story on Rappler
Add a comment
How does this make you feel?
Loading
There are no comments yet. Add your comment to start the conversation.